Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (1213)	12/10/1998 1:36:00 AM
From: David S.	Read Replies (1) \| Respond to of 1510

Hey bud: you must be the same John W that I caught over a year ago who was totally wrong on Thymitaq. You were crowing about how Agouron's PI had a lack of side effects. You were wrong about that, too since the PI's as a class seem to have similar side effects. You were crowing about the mutation profile and were wrong about that too. Gee, there must have been something you were right about - oh yeah, you took the award for pumping. You were caught as a hypster on the Agouron thread and here you go again. Since you work for Congress and are a biology whiz, maybe you can re-analyze the DNA on Monica's dress. PS - some of it's mine. Maybe if Agouron sells out, investors can come out whole.